

Apple Health PDL Drug Class Motions

Asthma and COPD Agents:

- ▶ Anticholinergics
- ▶ Phosphodiesterase 4 Inhibitors
- ▶ Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations
- ▶ Long Acting Muscarinic Agents

Asthma and COPD Agents:

▶ Recommendation:

- ▶ All products listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of one preferred product with the same indication before a non-preferred drug will be authorized unless contraindicated or not clinically appropriate.

Asthma and COPD Agents:

Motion: I move that all products in the drug classes listed on slide 2 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of one preferred product with the same indication before a non-preferred drug will be authorized unless contraindicated or not clinically appropriate.

- ▶ **Motion: Lee**
- ▶ **2nd: Brown**

Asthma and COPD Agents:

- ▶ Inhaled Corticosteroid Combinations
- ▶ Inhaled Corticosteroid

Asthma and COPD Agents:

▶ Recommendation:

- ▶ All products listed on slide 5 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Asthma and COPD Agents:

Motion: I move that all products in the drug classes listed on slide 5 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion:** Flatebo
- ▶ **2nd:** Schwilke

Asthma and COPD Agents: Monoclonal Antibodies

▶ Recommendation:

- ▶ All products in the Asthma and COPD Agents: Monoclonal Antibodies drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Asthma and COPD Agents: Monoclonal Antibodies

Motion: I move that all products in the Asthma and COPD Agents: Monoclonal Antibodies drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Storhaug**
- ▶ **2nd: Marcotte**

Hematopoietic Agents: Gaucher Disease

▶ Recommendation:

- ▶ All products in the Hematopoietic Agents: Gaucher Disease drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Hematopoietic Agents: Gaucher Disease

Motion: I move that all products in the Hematopoietic Agents: Gaucher Disease drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Buccola**
- ▶ **2nd: Brown**

Hematopoietic Agents: Sickle Cell Anemia

▶ Recommendation:

- ▶ All products in the Hematopoietic Agents: Sickle Cell Anemia drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Hematopoietic Agents: Sickle Cell Anemia

Motion: I move that all products in the Hematopoietic Agents: Sickle Cell Anemia drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Chawla**
- ▶ **2nd: Flatebo**

Hematopoietic Agents : Granulocyte Colony-Stimulating Factors (G-CSF)

► Recommendation:

- ▶ All products in the Hematopoietic Agents : Granulocyte Colony-Stimulating Factors (G-CSF) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of one preferred product with the same indication before a non-preferred drug will be authorized unless contraindicated or not clinically appropriate.

Hematopoietic Agents : Granulocyte Colony-Stimulating Factors (G-CSF)

Motion: I move that all products in the Hematopoietic Agents : Granulocyte Colony-Stimulating Factors (G-CSF) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of one preferred product with the same indication before a non-preferred drug will be authorized unless contraindicated or not clinically appropriate.

► **Motion: Brown**

► **2nd: Park**

Hematopoietic Agents : Erythropoiesis-Stimulating Agents (ESAS)

► Recommendation:

- ▶ All products in the Hematopoietic Agents: Erythropoiesis-Stimulating Agents (ESAS) drug class considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Hematopoietic Agents : Erythropoiesis-Stimulating Agents (ESAS)

Motion: I move that all products in the Hematopoietic Agents: Erythropoiesis-Stimulating Agents (ESAS) drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion:** Flatebo
- ▶ **2nd:** Marcotte

Immune Modulators and Oncology Agents

- ▶ Thalidomide Analogues
- ▶ Alkylating Agents – Oral
- ▶ Antineoplastics Misc – Oral
- ▶ BCL-2 Inhibitors – Oral
- ▶ Histone Deacetylase Inhibitors – Oral
- ▶ Isocitrate Dehydrogenase-1 (IDH1) Inhibitors – Oral
- ▶ Isocitrate Dehydrogenase-2 (IDH2) Inhibitors – Oral
- ▶ Janus Associated Kinase (JAK) Inhibitors – Oral

Immune Modulators and Oncology Agents Continued

- ▶ Proteasome Inhibitors – Oral
- ▶ XPO1 Inhibitors – Oral
- ▶ Antimetabolites – Oral
- ▶ Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral

Immune Modulators and Oncology Agents

► Recommendation:

- ▶ All products listed on slides 18 and 19 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Immune Modulators and Oncology Agents

Motion: I move that all products in the drug classes listed on slides 18 and 19 are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Marcotte**
- ▶ **2nd: Lee**

Hematopoietic Agents: Thrombopoiesis (TPO) Stimulating Proteins

► Recommendation:

- ▶ All products in the Hematopoietic Agents: Thrombopoiesis (TPO) Stimulating Proteins drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA.
- ▶ Products in this class may require prior authorization to determine medical necessity.
- ▶ All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

Hematopoietic Agents: Thrombopoiesis (TPO) Stimulating Proteins

Motion: I move that all products in the Hematopoietic Agents: Thrombopoiesis (TPO) Stimulating Proteins drug class are considered safe and efficacious for their medically accepted indications and are eligible for preferred status and grandfathering at the discretion of HCA. Products in this class may require prior authorization to determine medical necessity. All non-preferred products require a trial of two preferred products with the same indication before a non-preferred drug will be authorized unless contraindicated, not clinically appropriate, or only one product is preferred.

- ▶ **Motion: Schwilke**
- ▶ **2nd: Storhaug**